|
Synonyms: AVI6451 | compound 4 [PMID: 41406955]
Compound class:
Synthetic organic
Comment: AVI-6451 is an orally bioavailable inhibitor of the ADP-ribosylhydrolase Mac1 that is a validated antiviral target domain within the complex SARS-CoV-2 nsp3 (which also encodes the papain-like protease/PLpro) [1-3].
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Jaishankar P, Correy GJ, Matsui Y, Togo T, Rachman MM, Stevens MGV, Hantz ER, Zheng J, Diolaiti ME, Montano M et al.. (2026)
Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo. J Med Chem, 69 (1): 553-573. [PMID:41406955] |
|
2. Matsui M, Renslo AR, Jaishankar P, Gonciarz RL, Togo T, Rachman M, Fraser JS, Correy GJ, Shiochet BK, Neitz J et al.. (2025)
Mac1 inhibitors and uses thereof. Patent number: WO2025217212A1. Assignee: J David Gladstone Institutes, University of California Berkeley, University of California San Diego UCSD. Priority date: 08/04/2025. Publication date: 16/10/2025. |
|
3. Wang X, Butler WTW, Donald JR, Wang Y, Shaw AL, Schuller M, Fearon D, Aschenbrenner JC, Marples PG, Watt G et al.. (2026)
X-ray Crystallography-Guided Design and Synthesis of Cyclopentyl Heteroaryl Carboxylic Acid-Based Inhibitors of the SARS-CoV-2 Nsp3 Macrodomain (Mac1). J Med Chem, [Epub ahead of print]. [PMID:42439527] |